Earnings per share

12 Months Ended

Jun. 30, 2018

Note 37. Earnings per share


	Consolidated
	2018 A$’000			2017 A$’000			2016 A$’000

Loss after income tax attributable to the owners of Kazia Therapeutics Limited		(6,039	)		(10,670	)		(12,155	)
Non-controlling interest		—			—			93


Loss after income tax attributable to the owners of Kazia Therapeutics Limited		(6,039	)		(10,670	)		(12,062	)


	Number			Number			Number

Weighted average number of ordinary shares used in calculating basic earnings per share		48,376,525			467,833,849			427,431,910


Weighted average number of ordinary shares used in calculating diluted earnings per share		48,376,525			467,833,849			427,431,910


	Cents			Cents			Cents
	A$			A$			A$

Basic earnings per share		(12.48	)		(2.28	)		(2.82	)
Diluted earnings per share		(12.48	)		(2.28	)		(2.82	)

1,865,000 unlisted convertible notes with a face value of A$464,000, 4,798,266 unlisted options and 3,148,400 listed options have been excluded from the above calculations as they were antidilutive.